ADRB1 and ADBR2 Gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects

Current Eye Research

Volumn 39, Issue 11, 2014, Pages 1076-1080

  Messina Baas, Olga ^a   Pacheco Cuellar, Guillermo ^a   Toral López, Jaime ^a,b,c   Lara Huerta, Silvia Fanny ^a   Gonzalez Huerta, Luz Mariá ^a,c   Urueta Cuellar, Héctor ^a   Rivera Vega, Ma Refugio ^a   Babayan Mena, Ignacio ^a   Cuevas Covarrubias, Sergio A ^a,c  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b Secretaria de Finanzas del Distrito Federal   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

ADRB1 gene; ADRB2 gene; Betaxolol; Polymorphism

Indexed keywords

ARGININE; BETAXOLOL; GLUTAMIC ACID; GLUTAMINE; GLYCINE; SERINE; ADRB1 PROTEIN, HUMAN; ADRB2 PROTEIN, HUMAN; ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; EYE DROPS;

ADRB1 GENE; ADRB2 GENE; ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR PRESSURE; MALE; MEXICAN; MIDDLE AGED; NORMAL HUMAN; OCULAR HYPOTENSIVE RESPONSE; TREATMENT RESPONSE; VISUAL SYSTEM PARAMETERS; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; GENOTYPE; INTRAOCULAR HYPOTENSION; MEXICO; OCULOPLETHYSMOGRAPHY; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; BETAXOLOL; FEMALE; GENE FREQUENCY; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; INTRAOCULAR PRESSURE; MALE; MEXICO; MIDDLE AGED; OCULAR HYPOTENSION; OPHTHALMIC SOLUTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; TONOMETRY, OCULAR;

EID: 84911968171     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2014.900807     Document Type: Article

References (19)

1. Yarangümeli A, Kural G. Are there any benefits of Betoptic S (betaxolol HCl ophthalmic suspension) over other betablockers in the treatment of glaucoma? Expert Opin Pharmacother 2004;5:1071-1081.
2. Wax MB, Molinoff PB. Distribution and properties of betaadrenergic receptors in human iris-ciliary body. Invest Ophthalmol Vis Sci 1987;28:420-430.
3. DeGeorge Jr BR, Koch WJ. Beta blocker specificity: a building block toward personalized medicine. J Clin Invest 2007;117:86-89.
4. Baker JG. The selectivity of beta-Adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005;144:317-322.
5. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-Adrenergic signaling in heart failure? Circ Res 2003;93: 896-906.
6. Sidjanin DJ, McCarty CA, Patchett R, Smith E, Wilke RA. Pharmacogenetics of ophthalmic topical beta-blockers. Per Med 2008;5:377-385.
7. Geringer CC, Imami NR. Medical management of glaucoma. Int Ophthalmol Clin 2008;48:115-141.
8. Inan UU, Ermis SS, Orman A, Onrat E, Yucel A, Ozturk F, et al. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical tavoprost, bimatoprost, brimonidine and betaxolol. J Ocul Pharmacol Ther 2004;20:293-310.
9. Schwartz SG, Puckett BJ, Allen RC, Castillo IG, Leffler CT. Beta 1 adrenergic receptor polymorphisms and clinical efficacy of Betaxolol hydrochloride in normal volunteers. Ophthalmology 2005;112:2131-2136.
10. Inagaki Y, Mashima Y, Fuse N, Funayama T, Ohtake Y, Yasuda N, et al. Polymorphism of b-Adrenergic receptors and susceptibility to open-Angle glaucoma. Mol Vis 2006; 12:673-680.
11. Mason DA, Moore JD, Green SA, Liggett SB. A gain-offunction polymorphism in a G-protein coupling domain of the human b1-Adrenergic receptor. J Biol Chem 1999;274: 12670-12674.
12. Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Ra°stam L, et al. Polymorphism in the b1-Adrenergic receptor gene and hypertension. Circulation 2001;104:187-190.
13. Iwai C, Akita H, Kanazawa K, Shiga N, Terashima M, Matsuda Y, et al. Arg389Gly polymorphism of the human beta1-Adrenergic receptor in patients with nonfatal acute myocardial infarction. Am heart J 2003; 146:106-109.
14. Ellsworth DL, Coady S, Chen W, Srinivasan SR, Boerwinkle E, Berenson GS. Interactive effects between polymorphisms in the b-Adrenergic receptors and longitudinal hanges in obesity. Obesity Res 2005; 13:3-5.
15. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. b1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003;74:44-52.
16. Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, Borges A, et al. Impact of b1-Adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to Beta-blocker therapy. Am J Cardiol 2008;102:726-732.
17. Sandilands A, O'Shaughnessy KM. The functional significance of genetic variation within the b1-Adrenoceptor. Br J Clin Pharmacol 2005;60:235-243.
18. Fuchsjager-Mayrl G, Markovic MO, Losert D, Lucas T, Wachek V, Muller M, et al. Polymorphism of the b-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects. Mol Vision 2005;11:811-815.
19. McCarty CA, Burmester JK, Mukesh BN, Patchett RB, Wilke RA. Intraocular pressure response to topical betablockers associated with an ADRB2 single-nucleotide polymorphism. Arch Ophthalmol 2008;126:959-963